The Global Health Body Issues Warning Over Acute Scarcity of Obesity Injections

Less than 10% of people who could benefit from weight-loss injections including Wegovy are able to get them, warns the global health agency as it issues its inaugural advice on the medications.

Considering in excess of 1,000,000,000 people worldwide now classified as obese, it is calling for more widespread and fairer availability to GLP-1 medication.

Per estimates, more than two billion will be obese by 2030 without intervention.

"The latest guidelines recognises that obesity is a chronic disease that can be treated with holistic and continuous treatment," remarked its chief Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and logistical bottlenecks are significant hurdles to broad access to the jabs that can help people shift significant body mass, notes the agency.

Skinny Jab Shortage

Even under the present most favorable scenario, the production of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of those who need them, according to the WHO.

The advice encourages nations and manufacturers to widen availability, via approaches like patent sharing.

Exclusive production rights on the active ingredient – the primary component of a leading brand – is set to lapse in multiple countries in 2026.

How Weight-Loss Jabs Work

These medications imitate a body's own hormone to slow digestion, reduce hunger and increase satiety so individuals consume fewer calories.

People typically begin shedding pounds within a few weeks of beginning the once-weekly jabs.

Evidence suggests users may see weight return after a year of halting the treatment, when their normal hunger resume.

To be above a healthy weight raises your risk for contracting health problems, like diabetes, heart disease, stroke, and certain malignancies.

Obesity concerns individuals in every country and was linked to over three and a half million fatalities worldwide in 2024, according to the WHO.